COMMUNIQUÉS West-GlobeNewswire
-
OrthoPediatrics Corp. Reports First Quarter 2026 Financial Results and Increases 2026 Financial Guidance
30/04/2026 -
Larimar Therapeutics Publishes Cross-Species Findings Supporting Skin as a Surrogate for the Measurement of Frataxin in Tissues Clinically Relevant to Friedreich’s Ataxia
30/04/2026 -
Merit Medical Reports First Quarter 2026 Results and Updates Full-Year Guidance
30/04/2026 -
HCW Biologics Announces Adjournment of Special Meeting of Stockholders Due to Lack of Quorum
30/04/2026 -
Stryker reports first quarter 2026 operating results
30/04/2026 -
Century Therapeutics Selected for Oral Presentation of CNTY‑813 Preclinical Data at the American Diabetes Association 86th Scientific Sessions
30/04/2026 -
RadNet and Trinity Health’s Saint Alphonsus Health System Launch a Multi-Site Joint Venture in Boise, Idaho, to Include a Broad Technology Deployment of DeepHealth Solutions
30/04/2026 -
BioStem Technologies to Host First Quarter 2026 Financial Results Conference Call on May 14, 2026
30/04/2026 -
Echo IQ Announces EchoSolv AS Deployed into Mount Sinai Health System
30/04/2026 -
Cocrystal Pharma Presentation at ICAR 2026 Highlights Mechanism of Action and Clinical Advancement of CDI-988 for the Prevention and Treatment of Norovirus Infection
30/04/2026 -
Cue Biopharma Names Shao-Lee Lin M.D., Ph.D., CEO, President and Board Director to Lead Continued Growth and Transformation into a Clinical-Stage Company
30/04/2026 -
The Ensign Group Reports First Quarter 2026 Results; Raises 2026 Annual Earnings and Revenue Guidance
30/04/2026 -
CapsoVision to Release First Quarter 2026 Financial Results on May 14, 2026
30/04/2026 -
CooperCompanies Announces Release Date for Second Quarter 2026
30/04/2026 -
Cue Biopharma Expands Pipeline with Exclusive License from Ascendant Health Sciences Ltd. for Clinical-Stage Dual-Mechanism Anti-IgE Antibody
30/04/2026 -
Trevi Therapeutics Announces Oral Presentation and Multiple Posters Accepted at the American Thoracic Society (ATS) 2026 International Conference
30/04/2026 -
Resmed Inc. Announces Results for the Third Quarter of Fiscal Year 2026
30/04/2026 -
Aligos Therapeutics to Announce 1st Quarter 2026 Financial Results on May 7, 2026
30/04/2026 -
Resmed Chief Financial Officer Brett Sandercock to Retire; Aaron Bloomer Appointed as Successor
30/04/2026
Pages